Open Access Highly Accessed Research article

Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo

Ivana Z Matić1, Marija Đorđić1, Nađa Grozdanić1, Ana Damjanović1, Branka Kolundžija1, Aleksandra Erić-Nikolić1, Radan Džodić12, Miomir Šašić1, Srđan Nikolić1, Danijela Dobrosavljević23, Sanvila Rašković24, Slađana Andrejević4, Dušica Gavrilović1, Oscar J Cordero5 and Zorica D Juranić1*

Author Affiliations

1 Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000, Belgrade, Serbia

2 School of Medicine, University of Belgrade, 11000, Belgrade, Serbia

3 Clinic of Dermatovenereology, Clinical Center of Serbia, 11000, Belgrade, Serbia

4 Institute of Immunology and Allergology, Clinical Center of Serbia, 11000, Belgrade, Serbia

5 Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, CIBUS Building, r/Lopez de Marzoa s/n, Campus Vida, 15782, Santiago de Compostela, Spain

For all author emails, please log on.

BMC Immunology 2012, 13:48  doi:10.1186/1471-2172-13-48

Published: 21 August 2012



Dipeptidyl peptidase IV, a multifunctional serine protease, is implicated in regulation of malignant transformation, promotion and further progression of cancer, exerting tumor-suppressing or even completely opposite - tumor-promoting activities.

The aim of present research was to determine the serum DPPIV activity, as well as the percentages of CD26+ lymphocytes, CD26+ overall white blood cells and the mean fluorescence intensity of CD26 expression on lymphocytes in patients with melanoma, people with vitiligo and in healthy controls.


The activity of DPPIV in serum was determined by colorimetric test. Expression of DPPIV (as CD26) on immunocompetent peripheral white blood cells was done using flow cytometry analysis.


Data from our study show for the first time statistically significant decrease: in the serum DPPIV activity, in the percentage of CD26+ overall white blood cells and in the percentage of lymphocytes in patients with melanoma in comparison to healthy control people. In addition, significantly lower serum DPPIV activity was found in the group of patients with melanoma in relation to people with vitiligo too.


This study indicates the need for exploring the cause and the importance of the disturbances in the serum DPPIV activity and in the CD26 expression on immunocompetent cells in complex molecular mechanisms underlying the development and progression of melanoma.

CD26 expression; DPPIV serum activity; Melanoma; Vitiligo